These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

679 related articles for article (PubMed ID: 11342973)

  • 21. Expression of MMP2, MMP9, MT1-MMP, TIMP1, and TIMP2 mRNA in valvular lesions of the heart.
    Soini Y; Satta J; Määttä M; Autio-Harmainen H
    J Pathol; 2001 Jun; 194(2):225-31. PubMed ID: 11400152
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Occurrence of matrix metalloproteinases and tissue inhibitors of metalloproteinases in tuberculous pleuritis.
    Hoheisel G; Sack U; Hui DS; Huse K; Chan KS; Chan KK; Hartwig K; Schuster E; Scholz GH; Schauer J
    Tuberculosis (Edinb); 2001; 81(3):203-9. PubMed ID: 11466032
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Basement membrane remodeling in skeletal muscles of patients with limb ischemia involves regulation of matrix metalloproteinases and tissue inhibitor of matrix metalloproteinases.
    Baum O; Ganster M; Baumgartner I; Nieselt K; Djonov V
    J Vasc Res; 2007; 44(3):202-13. PubMed ID: 17337906
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in bladder carcinoma.
    Xu K; Hou S; Du Z
    Chin Med J (Engl); 2002 May; 115(5):743-5. PubMed ID: 12133547
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine.
    Eissa S; Ali-Labib R; Swellam M; Bassiony M; Tash F; El-Zayat TM
    Eur Urol; 2007 Nov; 52(5):1388-96. PubMed ID: 17466450
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes.
    Ries C; Loher F; Zang C; Ismair MG; Petrides PE
    Clin Cancer Res; 1999 May; 5(5):1115-24. PubMed ID: 10353746
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Matrix metalloproteinase expression in the recurrence of superficial low grade bladder transitional cell carcinoma.
    Choi YD; Cho NH; Ahn HS; Cho KS; Cho SY; Yang WJ
    J Urol; 2007 Mar; 177(3):1174-8. PubMed ID: 17296440
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinase in uterine endometrial carcinoma and a correlation between expression of matrix metalloproteinase-7 and prognosis.
    Misugi F; Sumi T; Okamoto E; Nobeyama H; Hattori K; Yoshida H; Matsumoto Y; Yasui T; Honda K; Ishiko O
    Int J Mol Med; 2005 Oct; 16(4):541-6. PubMed ID: 16142384
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Expression of matrix metalloproteinase-2, 9 and it's tissue inhibitor-1, 2 in endometrial carcinoma].
    Guo W; Chen G; Zhu C; Wang H
    Zhonghua Fu Chan Ke Za Zhi; 2002 Oct; 37(10):604-7. PubMed ID: 12487935
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantitative estimation of matrix metalloproteinases 2 and 7 (MMP-2, MMP-7) and tissue inhibitors of matrix metalloproteinases 1 and 2 (TIMP-1, TIMP-2) in colorectal carcinoma tissue samples.
    Pesta M; Holubec L; Topolcan O; Cerna M; Rupert K; Holubec LS; Treska V; Kormunda S; Elgrova L; Finek J; Cerny R
    Anticancer Res; 2005; 25(5):3387-91. PubMed ID: 16101153
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer.
    Grignon DJ; Sakr W; Toth M; Ravery V; Angulo J; Shamsa F; Pontes JE; Crissman JC; Fridman R
    Cancer Res; 1996 Apr; 56(7):1654-9. PubMed ID: 8603416
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The prognostic value of angiogenesis and metastasis-related genes for progression of transitional cell carcinoma of the renal pelvis and ureter.
    Inoue K; Kamada M; Slaton JW; Fukata S; Yoshikawa C; Tamboli P; Dinney CP; Shuin T
    Clin Cancer Res; 2002 Jun; 8(6):1863-70. PubMed ID: 12060629
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of matrix metalloproteinases in human transitional cell carcinoma of the urinary bladder.
    Sumi T; Yoshida H; Hyun Y; Yasui T; Matsumoto Y; Hattori K; Sugimura K; Kawashima H; Nakatani T; Ishiko O
    Oncol Rep; 2003; 10(2):345-9. PubMed ID: 12579270
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential expression of matrix metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis.
    Määttä M; Soini Y; Liakka A; Autio-Harmainen H
    Clin Cancer Res; 2000 Jul; 6(7):2726-34. PubMed ID: 10914717
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer.
    Oberg A; Höyhtyä M; Tavelin B; Stenling R; Lindmark G
    Anticancer Res; 2000; 20(2B):1085-91. PubMed ID: 10810401
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Elevation of serum levels of matrix metalloproteinase-2 and -3 as new predictors of recurrence in patients with urothelial carcinoma.
    Gohji K; Fujimoto N; Komiyama T; Fujii A; Ohkawa J; Kamidono S; Nakajima M
    Cancer; 1996 Dec; 78(11):2379-87. PubMed ID: 8941010
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased expression of membrane-type matrix metalloproteinase-1 is correlated with poor prognosis in patients with osteosarcoma.
    Uchibori M; Nishida Y; Nagasaka T; Yamada Y; Nakanishi K; Ishiguro N
    Int J Oncol; 2006 Jan; 28(1):33-42. PubMed ID: 16327977
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Assay of matrix metalloproteinase levels and their endogenous inhibitors in patients with laryngeal carcinoma].
    Klisho EV; Savenkova OV; Kondakova IV; Perel'muter VM; Choĭnzonov EL; Shishkin DA
    Vopr Onkol; 2007; 53(1):26-31. PubMed ID: 17649730
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Matrix metalloproteinase-9 (MMP-9) immunoreactive protein in urinary bladder cancer: a marker of favorable prognosis.
    Vasala K; Pääkko P; Turpeenniemi-Hujanen T
    Anticancer Res; 2008; 28(3B):1757-61. PubMed ID: 18630455
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 is correlated with poor prognostic variables in patients with thymic epithelial tumors.
    Sogawa K; Kondo K; Fujino H; Takahashi Y; Miyoshi T; Sakiyama S; Mukai K; Monden Y
    Cancer; 2003 Nov; 98(9):1822-9. PubMed ID: 14584061
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.